Amgen, colorectal and FDA
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival,
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...
GlobalData on MSN13d
Amgen’s Imdylltra wins conditional MHRA licence for lung cancerAmgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback